LT3347352T - Terapiniai junginiai, naudotini živ viruso infekcijos profilaktikai arba terapiniam gydymui - Google Patents

Terapiniai junginiai, naudotini živ viruso infekcijos profilaktikai arba terapiniam gydymui

Info

Publication number: LT3347352T
Authority: LT; Lithuania
Prior art keywords: therapeutic; prophylactic; virus infection; compounds useful; hiv virus
Prior art date: 2016-08-19

Application number

LTEP17758388.7T

Other languages

English (en)

Inventor

Michael Graupe

Steven J. HENRY

John O. Link

Charles William Rowe

Roland D. Saito

Scott D. Schroeder

Dimitrios Stefanidis

Winston C. Tse

Jennifer R. Zhang

Original Assignee

Gilead Sciences, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-08-19

Filing date

2017-08-17

Publication date

2019-08-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59714166&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3347352(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2017-08-17 Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.

2019-08-12 Publication of LT3347352T publication Critical patent/LT3347352T/lt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/02—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms
- C07C317/08—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Virology (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Engineering & Computer Science (AREA)
Medicinal Preparation (AREA)
Oil, Petroleum & Natural Gas (AREA)
Inorganic Chemistry (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Dermatology (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

LTEP17758388.7T 2016-08-19 2017-08-17 Terapiniai junginiai, naudotini živ viruso infekcijos profilaktikai arba terapiniam gydymui LT3347352T (lt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201662377312P	2016-08-19	2016-08-19
US201762457555P	2017-02-10	2017-02-10
PCT/US2017/047416 WO2018035359A1 (en)	2016-08-19	2017-08-17	Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection

Publications (1)

Publication Number	Publication Date
LT3347352T true LT3347352T (lt)	2019-08-12

Family

ID=59714166

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
LTEP17758388.7T LT3347352T (lt)	2016-08-19	2017-08-17	Terapiniai junginiai, naudotini živ viruso infekcijos profilaktikai arba terapiniam gydymui
LTEP19178148.3T LT3597646T (lt)	2016-08-19	2017-08-17	Terapiniai junginiai, naudotini živ viruso infekcijos profilaktikai ir terapiniam gydymui
LTPA2023501C LTPA2023501I1 (lt)	2016-08-19	2023-01-05

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
LTEP19178148.3T LT3597646T (lt)	2016-08-19	2017-08-17	Terapiniai junginiai, naudotini živ viruso infekcijos profilaktikai ir terapiniam gydymui
LTPA2023501C LTPA2023501I1 (lt)	2016-08-19	2023-01-05

Country Status (42)

Country	Link
US (3)	US10071985B2 (lt)
EP (3)	EP3597646B1 (lt)
JP (4)	JP6716785B2 (lt)
KR (4)	KR20230011471A (lt)
CN (2)	CN111793061A (lt)
AU (4)	AU2017312102B2 (lt)
BR (2)	BR122020001791B1 (lt)
CA (1)	CA3021227C (lt)
CL (1)	CL2019000415A1 (lt)
CO (1)	CO2019001379A2 (lt)
CR (1)	CR20190084A (lt)
CY (2)	CY1122296T1 (lt)
DK (2)	DK3347352T3 (lt)
DO (1)	DOP2019000033A (lt)
EC (1)	ECSP19011209A (lt)
ES (2)	ES2746374T3 (lt)
FI (1)	FI3597646T3 (lt)
FR (1)	FR22C1063I2 (lt)
HK (1)	HK1256904B (lt)
HR (1)	HRP20231018T1 (lt)
HU (3)	HUE063811T2 (lt)
IL (1)	IL264644B (lt)
JO (1)	JOP20180123A1 (lt)
LT (3)	LT3347352T (lt)
MA (2)	MA42795B1 (lt)
MX (1)	MX369307B (lt)
MY (1)	MY191466A (lt)
NL (1)	NL301212I2 (lt)
NO (1)	NO2022059I1 (lt)
NZ (1)	NZ750706A (lt)
PE (2)	PE20211427A1 (lt)
PH (1)	PH12019500335A1 (lt)
PL (2)	PL3597646T3 (lt)
PT (2)	PT3347352T (lt)
SA (1)	SA519401123B1 (lt)
SG (2)	SG10201912535VA (lt)
SI (2)	SI3347352T1 (lt)
TW (3)	TW202138365A (lt)
UA (1)	UA121630C2 (lt)
UY (1)	UY37367A (lt)
WO (1)	WO2018035359A1 (lt)
ZA (1)	ZA201901430B (lt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2553449T3 (es)	2011-07-06	2015-12-09	Gilead Sciences, Inc.	Compuestos para el tratamiento de VIH
WO2015130964A1 (en)	2014-02-28	2015-09-03	Gilead Sciences, Inc.	Therapeutic compounds
CN111793061A (zh)	2016-08-19	2020-10-20	吉利德科学公司	用于预防性或治疗性治疗hiv病毒感染的治疗性化合物
AR112412A1 (es)	2017-08-17	2019-10-23	Gilead Sciences Inc	Formas de sal de colina de un inhibidor de la cápside del vih
AR112413A1 (es) *	2017-08-17	2019-10-23	Gilead Sciences Inc	Formas sólidas de un inhibidor de la cápside del vih
KR102587510B1 (ko)	2018-02-15	2023-10-11	길리애드 사이언시즈, 인코포레이티드	피리딘 유도체 및 hiv 감염을 치료하기 위한 그의 용도
EP3752496B1 (en) *	2018-02-16	2023-07-05	Gilead Sciences, Inc.	Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection
WO2019246545A1 (en) *	2018-06-21	2019-12-26	Drexel University	Small-molecule hiv-1 capsid protein inhibitors and methods using same
EP3823621A1 (en) *	2018-07-16	2021-05-26	Gilead Sciences, Inc.	Capsid inhibitors for the treatment of hiv
EP3833436A1 (en) *	2018-08-09	2021-06-16	VIIV Healthcare UK (No.5) Limited	Inhibitors of human immunodeficiency virus replication
US20220089598A1 (en)	2018-09-14	2022-03-24	Viiv Healthcare Uk (No. 5) Limited	Inhibitors of human immunodeficiency virus replication
JP7433303B2 (ja)	2018-09-20	2024-02-19	ヴィーブヘルスケアユーケー（ナンバー５）リミテッド	ヒト免疫不全ウイルス複製の阻害剤
ES2971987T3 (es)	2018-10-24	2024-06-10	Viiv Healthcare Uk No 5 Ltd	Inhibidores de la replicación del virus de inmunodeficiencia humana
US11541055B2 (en)	2018-10-24	2023-01-03	VIIV Healthcare UK (No.5) Limited	Inhibitors of human immunodeficiency virus replication
JP7500555B2 (ja)	2018-10-25	2024-06-17	ヴィーブヘルスケアユーケー（ナンバー５）リミテッド	ヒト免疫不全ウイルス複製の阻害剤
JP7526174B2 (ja) *	2018-10-29	2024-07-31	ヴィーブヘルスケアユーケー（ナンバー５）リミテッド	キナゾリニル－インダゾール誘導体及びそのヒト免疫不全ウイルス複製の阻害剤としてのその使用
US20210395248A1 (en)	2018-11-05	2021-12-23	VIIV Healthcare UK (No.5) Limited	Inhibitors of human immunodeficiency virus replication
US20210379071A1 (en)	2018-11-05	2021-12-09	VIIV Healthcare UK (No.5) Limited	Inhibitors of human immunodeficiency virus replication
KR20210137434A (ko)	2019-01-25	2021-11-17	브라운 유니버시티	연령 관련 염증 및 장애를 치료, 예방 또는 역전시키기 위한 조성물 및 방법
UY38559A (es)	2019-02-01	2020-07-31	Viiv Healthcare Uk No 5 Ltd	Inhibidores de la replicación del virus de la inmunodeficiencia humana
US20220211704A1 (en)	2019-04-30	2022-07-07	Viiv Healthcare Uk (No. 5) Limited	Inhibitors of human immunodeficiency virus replication
RU2717101C1 (ru)	2019-06-03	2020-03-18	Андрей Александрович Иващенко	Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
PL3986561T3 (pl)	2019-06-19	2024-06-10	VIIV Healthcare UK (No.5) Limited	Pochodne pirydo[2,3-d]pirymidyny jako inhibitory replikacji ludzkiego wirusa niedoboru odporności
EP4038068A1 (en)	2019-10-01	2022-08-10	VIIV Healthcare UK (No.5) Limited	N-substituted-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl derivatives as inhibitors of the human immunodeficiency virus replication
WO2021064570A1 (en)	2019-10-01	2021-04-08	VIIV Healthcare UK (No.5) Limited	N-substututed-6-oxo-1,6-dihydropyrimidine-2-yl derivatives as inhibitors of the human immunodeficiency virus replication
TW202128648A (zh)	2019-10-04	2021-08-01	英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司	人類免疫不全病毒複製之抑制劑
JP2022551691A (ja)	2019-10-08	2022-12-13	ビーブ、ヘルスケア、ユーケー、（ナンバー５）、リミテッド	ヒト免疫不全ウイルスの複製阻害剤
CA3157275A1 (en) *	2019-11-26	2021-06-03	Elena BEKERMAN	Capsid inhibitors for the prevention of hiv
WO2021107066A1 (ja)	2019-11-28	2021-06-03	塩野義製薬株式会社	インテグラーゼ阻害剤及び抗ｈｉｖ薬を組み合わせることを特徴とするｈｉｖ感染症の予防及び治療用医薬
US20230023968A1 (en) *	2019-11-29	2023-01-26	Jiangsu Hengrui Medicine Co., Ltd.	Fused pyridine ring derivative, preparation method therefor, and pharmaceutical use thereof
CN116098917A (zh) *	2020-02-27	2023-05-12	河南真实生物科技有限公司	核苷类化合物在治疗冠状病毒感染性疾病中的用途
US20230355626A1 (en)	2020-03-06	2023-11-09	VIIV Healthcare UK (No.5) Limited	Inhibitors of human immunodeficiency virus replication
EP4114527A1 (en)	2020-03-06	2023-01-11	VIIV Healthcare UK (No.5) Limited	Inhibitors of human immunodeficiency virus replication
AR121620A1 (es)	2020-03-20	2022-06-22	Gilead Sciences Inc	Profármacos de nucleósidos 4-c-sustituidos-2-halo-2-deoxiadenosina y métodos de preparación y uso de los mismos
EP4135702A1 (en)	2020-04-15	2023-02-22	VIIV Healthcare UK (No.5) Limited	Inhibitors of human immunodeficiency virus replication
EP4153181A1 (en)	2020-05-21	2023-03-29	Gilead Sciences, Inc.	Pharmaceutical compositions comprising bictegravir
CN115996925A (zh) *	2020-06-25	2023-04-21	吉利德科学公司	用于治疗hiv的衣壳抑制剂
TW202406932A (zh)	2020-10-22	2024-02-16	美商基利科學股份有限公司	介白素2-Fc融合蛋白及使用方法
AU2021377614A1 (en)	2020-11-11	2023-06-22	Gilead Sciences, Inc.	METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES
WO2022159877A1 (en) *	2021-01-25	2022-07-28	Brii Biosciences, Inc.	Combination therapy for hiv with adenosine derivative and capsid inhibitors
CN118159529A (zh) *	2021-05-28	2024-06-07	江苏恒瑞医药股份有限公司	一种稠合吡啶环衍生物的可药用盐、晶型及其制备方法
KR20230018690A (ko)	2021-07-30	2023-02-07	(주) 에빅스젠	둥근이질풀 추출물을 유효성분으로 포함하는, 바이러스성 질환 치료 및 개선용 조성물
KR20230019059A (ko)	2021-07-30	2023-02-07	(주) 에빅스젠	연전초 추출물을 유효성분으로 포함하는, 바이러스성 질환 완화 및 개선용 조성물
TW202342448A (zh)	2021-12-03	2023-11-01	美商基利科學股份有限公司	用於ｈｉｖ病毒感染之治療性化合物
EP4440702A1 (en)	2021-12-03	2024-10-09	Gilead Sciences, Inc.	Therapeutic compounds for hiv virus infection
TW202342447A (zh) *	2021-12-03	2023-11-01	美商基利科學股份有限公司	用於ｈｉｖ病毒感染之治療性化合物
TWI843506B (zh)	2022-04-06	2024-05-21	美商基利科學股份有限公司	橋聯三環胺甲醯基吡啶酮化合物及其用途
TW202402280A (zh) *	2022-07-01	2024-01-16	美商基利科學股份有限公司	可用於ｈｉｖ病毒感染之疾病預防性或治療性治療的治療性化合物
WO2024044477A1 (en)	2022-08-26	2024-02-29	Gilead Sciences, Inc.	Dosing and scheduling regimen for broadly neutralizing antibodies
WO2024076915A1 (en)	2022-10-04	2024-04-11	Gilead Sciences, Inc.	4'-thionucleoside analogues and their pharmaceutical use
KR20240061218A (ko)	2022-10-31	2024-05-08	주식회사 이보드	복합 단열재 및 제조방법
WO2024163262A2 (en)	2023-01-30	2024-08-08	Merck Sharp & Dohme Llc	Prodrugs of 4'-substituted nucleoside reverse transcriptase inhibitors
WO2024220624A1 (en)	2023-04-19	2024-10-24	Gilead Sciences, Inc.	Dosing regimen of capsid inhibitor
CN116675675A (zh) *	2023-06-05	2023-09-01	北京康立生医药技术开发有限公司	一种艾滋病治疗药物来那卡帕韦中间体化合物的制备方法

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816570A (en)	1982-11-30	1989-03-28	The Board Of Regents Of The University Of Texas System	Biologically reversible phosphate and phosphonate protective groups
US4968788A (en)	1986-04-04	1990-11-06	Board Of Regents, The University Of Texas System	Biologically reversible phosphate and phosphonate protective gruops
JP3347723B2 (ja)	1990-06-13	2002-11-20	グラツィエル，アーノルド	含リンプロドラッグ
ATE167679T1 (de)	1990-09-14	1998-07-15	Acad Of Science Czech Republic	Wirkstoffvorläufer von phosphonaten
US5922695A (en)	1996-07-26	1999-07-13	Gilead Sciences, Inc.	Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5935946A (en)	1997-07-25	1999-08-10	Gilead Sciences, Inc.	Nucleotide analog composition and synthesis method
SI2682397T1 (sl)	2000-07-21	2017-08-31	Gilead Sciences, Inc.	Predzdravila fosfonatnih nukleotidnih analogov in postopki za selekcijo in izdelavo le-teh
JP4300108B2 (ja)	2001-06-27	2009-07-22	スミスクラインビーチャムコーポレーション	ジペプチジルペプチダーゼ阻害剤としてのピロリジン類
ATE370943T1 (de)	2001-06-27	2007-09-15	Smithkline Beecham Corp	Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren
SI1441734T1 (sl)	2001-10-26	2007-08-31	Angeletti P Ist Richerche Bio	Dihidropirimidin karboksamidni inhibitorji HIV-integraze
US7642277B2 (en)	2002-12-04	2010-01-05	Boehringer Ingelheim International Gmbh	Non-nucleoside reverse transcriptase inhibitors
US20040186151A1 (en)	2003-02-12	2004-09-23	Mjalli Adnan M.M.	Substituted azole derivatives as therapeutic agents
SG182849A1 (en)	2003-04-25	2012-08-30	Gilead Sciences Inc	Antiviral phosphonate analogs
DE602005023224D1 (de)	2004-02-27	2010-10-07	Schering Corp	Neuartige Verbindungen als Hemmer von Hepatitis C-Virus NS3-Serinprotease
US7429604B2 (en)	2004-06-15	2008-09-30	Bristol Myers Squibb Company	Six-membered heterocycles useful as serine protease inhibitors
US7453002B2 (en)	2004-06-15	2008-11-18	Bristol-Myers Squibb Company	Five-membered heterocycles useful as serine protease inhibitors
US7871991B2 (en)	2004-07-27	2011-01-18	Gilead Sciences, Inc.	Phosphonate analogs of HIV inhibitor compounds
US8067587B2 (en)	2005-07-28	2011-11-29	Lenroc Company	Process for the production of monoalkali metal cyanurates
EP1912989A2 (en)	2005-08-05	2008-04-23	AstraZeneca AB	Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators
AU2006325754B2 (en)	2005-12-14	2012-04-12	Bristol-Myers Squibb Company	Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIa inhibitors
JP5269761B2 (ja)	2006-04-12	2013-08-21	メルク・シャープ・アンド・ドーム・コーポレーション	ピリジルアミドｔ型カルシウムチャンネルアンタゴニスト
US7647464B2 (en)	2006-04-28	2010-01-12	At&T Intellectual Property, I,L.P.	Methods, systems, and products for recording media to a restoration server
WO2008013622A2 (en)	2006-07-27	2008-01-31	E. I. Du Pont De Nemours And Company	Fungicidal azocyclic amides
US8124811B2 (en)	2007-03-20	2012-02-28	Allylix, Inc.	Fragrance and methods for production of 5-epi-β-vetivone, 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-2,6-dien-8-one, and 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-1,6-dien-8-one
CN101702908A (zh)	2007-03-23	2010-05-05	麻萨诸塞州大学	Hiv-1蛋白酶抑制剂
EP2162432A2 (en)	2007-06-29	2010-03-17	Gilead Sciences, Inc.	Antiviral compounds
AU2008274185B2 (en)	2007-07-12	2014-07-03	Janssen Sciences Ireland Uc	Crystalline form of (E) 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2 pyrimidinyl]amino]benzonitrile
CN101754974B (zh)	2007-07-19	2016-02-03	Msd意大利有限公司	作为抗病毒剂的大环化合物
JP2011500808A (ja)	2007-10-24	2011-01-06	メルク・シャープ・エンド・ドーム・コーポレイション	複素環アミドｔ型カルシウムチャネルアンタゴニスト
MX2010004530A (es)	2007-10-24	2010-05-14	Merck Sharp & Dohme	Antagonistas de los canales de calcio tipo t de heterociclo fenil amida.
CA2707418C (en)	2007-11-16	2013-11-19	Boehringer Ingelheim International Gmbh	Inhibitors of human immunodeficiency virus replication
ES2380648T3 (es)	2008-03-13	2012-05-17	Bristol-Myers Squibb Company	Derivados de piridazina como inhibidores del factor XIA
ES2467108T3 (es)	2008-12-09	2014-06-11	Gilead Sciences, Inc.	Moduladores de receptores tipo toll
SG173822A1 (en)	2009-02-25	2011-09-29	Bigtec Private Ltd	Probes and primers for detection of chikungunya
US8338441B2 (en)	2009-05-15	2012-12-25	Gilead Sciences, Inc.	Inhibitors of human immunodeficiency virus replication
US20110274648A1 (en)	2009-11-11	2011-11-10	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
WO2011094890A1 (en)	2010-02-02	2011-08-11	Argusina Inc.	Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
WO2011139637A1 (en)	2010-05-03	2011-11-10	Philadelphia Health & Education Corporation	Small-molecule modulators of hiv-1 capsid stability and methods thereof
WO2011143772A1 (en)	2010-05-21	2011-11-24	Boehringer Ingelheim International Gmbh	Inhibitors of hiv replication
CA2802308C (en)	2010-07-02	2018-08-28	Lianhong Xu	Napht-2-ylacetic acid derivatives to treat aids
AP2013006707A0 (en)	2010-07-02	2013-02-28	Gilead Sciences Inc	2-Quinolinyl-acetic acid derivatives as HIV antiviral compounds
CN102464654B (zh)	2010-11-12	2016-01-13	上海泓博智源医药技术有限公司	抗病毒化合物
KR102129247B1 (ko)	2011-03-23	2020-07-06	트레베나, 인코포레이티드.	오피오이드 수용체 리간드와 그 용도 및 제조방법
KR20140027295A (ko)	2011-04-21	2014-03-06	길리애드 사이언시즈, 인코포레이티드	벤조티아졸 화합물 및 이들의 약학적 용도
ES2553449T3 (es)	2011-07-06	2015-12-09	Gilead Sciences, Inc.	Compuestos para el tratamiento de VIH
CN102863512B (zh)	2011-07-07	2016-04-20	上海泓博智源医药技术有限公司	抗病毒化合物
JP5651275B2 (ja)	2011-08-16	2015-01-07	ギリアードサイエンシスインコーポレーテッド	テノホビルアラフェナミドヘミフマレート
WO2013091096A1 (en)	2011-12-20	2013-06-27	Boehringer Ingelheim International Gmbh	Condensed triclyclic compounds as inhibitors of hiv replication
CN105121418A (zh)	2012-04-20	2015-12-02	吉利德科学公司	苯并噻唑-6-基乙酸衍生物及其治疗hiv感染的用途
GB201213087D0 (en)	2012-07-24	2012-09-05	Medical Res Council	Inhibition of HIV-1 infection
US9447134B2 (en)	2012-08-17	2016-09-20	Brandeis University	Compounds and methods for treating mammalian gastrointestinal microbial infections
SI3608325T1 (sl)	2012-12-21	2022-09-30	Gilead Sciences, Inc.	Policiklične-karbamoilpiridonske spojine in njihova farmacevtska uporaba
RU2015131006A (ru)	2012-12-27	2017-01-30	Джапан Тобакко Инк.	ЗАМЕЩЕННОЕ ПРОИЗВОДНОЕ СПИРОПИРИДО[1,2-a]ПИРАЗИНА И ЕГО ПРИМЕНЕНИЕ В МЕДИЦИНЕ В КАЧЕСТВЕ ИНГИБИТОРА ИНТЕГРАЗЫ ВИРУСА ИММУНОДЕФИЦИТА ЧЕЛОВЕКА (ВИЧ)
US9220710B2 (en)	2013-01-09	2015-12-29	Gilead Sciences, Inc.	Therapeutic compounds
EP2943493B1 (en)	2013-01-09	2017-08-02	Gilead Sciences, Inc.	Therapeutic compounds for the treatment of viral infections
TW201443037A (zh) *	2013-01-09	2014-11-16	Gilead Sciences Inc	治療用化合物
EP2769722A1 (en)	2013-02-22	2014-08-27	Ruprecht-Karls-Universität Heidelberg	Compounds for use in inhibiting HIV capsid assembly
US20140296266A1 (en)	2013-03-01	2014-10-02	Gilead Sciences, Inc.	Therapeutic compounds
TWI706945B (zh) *	2013-03-01	2020-10-11	美商基利科學股份有限公司	供治療反轉錄病毒科病毒感染之治療性化合物
GB201312991D0 (en)	2013-07-19	2013-09-04	Isis Innovation	Process
EA029259B1 (ru)	2013-10-24	2018-02-28	Бристол-Маерс Сквибб Компани	Ингибиторы репликации вируса иммунодефицита
WO2015130964A1 (en)	2014-02-28	2015-09-03	Gilead Sciences, Inc.	Therapeutic compounds
WO2015130966A1 (en)	2014-02-28	2015-09-03	Gilead Sciences, Inc.	Antiviral agents
JP6491321B2 (ja) *	2014-08-29	2019-03-27	ギリアードサイエンシーズ，インコーポレイテッド	抗レトロウイルス剤
WO2016040084A1 (en)	2014-09-09	2016-03-17	Bristol-Myers Squibb Company	Inhibitors of human immunodeficiency virus replication
ES2735087T3 (es)	2014-12-24	2019-12-16	Gilead Sciences Inc	Compuestos de pirimidina fusionados para el tratamiento de VIH
TW202237569A (zh)	2014-12-24	2022-10-01	美商基利科學股份有限公司	喹唑啉化合物
UY36648A (es)	2015-04-23	2016-11-30	Bristol Myers Squibb Company Una Corporación Del Estado De Delaware	Inhibidores de la replicación del virus de inmunodeficiencia humana
EP3286166B1 (en)	2015-04-23	2020-05-13	VIIV Healthcare UK (No.5) Limited	Inhibitors of human immunodeficiency virus replication
KR101974793B1 (ko) *	2015-07-06	2019-05-02	길리애드 사이언시즈, 인코포레이티드	Cot 조정제 및 그의 사용 방법
US10171985B1 (en)	2015-07-22	2019-01-01	Ginko LLC	Method and apparatus for data sharing
CN111793061A (zh)	2016-08-19	2020-10-20	吉利德科学公司	用于预防性或治疗性治疗hiv病毒感染的治疗性化合物
JOP20180009A1 (ar)	2017-02-06	2019-01-30	Gilead Sciences Inc	مركبات مثبط فيروس hiv
TW201906834A (zh)	2017-05-02	2019-02-16	英商Viiv醫療保健英國(No.5)有限公司	人類免疫不全病毒複製之抑制劑
AR112413A1 (es)	2017-08-17	2019-10-23	Gilead Sciences Inc	Formas sólidas de un inhibidor de la cápside del vih
AR112412A1 (es)	2017-08-17	2019-10-23	Gilead Sciences Inc	Formas de sal de colina de un inhibidor de la cápside del vih
KR102587510B1 (ko)	2018-02-15	2023-10-11	길리애드 사이언시즈, 인코포레이티드	피리딘 유도체 및 hiv 감염을 치료하기 위한 그의 용도
EP3752496B1 (en)	2018-02-16	2023-07-05	Gilead Sciences, Inc.	Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection
US10911396B2 (en)	2018-06-28	2021-02-02	Paypal, Inc.	Mid-tier messaging system
EP3823621A1 (en)	2018-07-16	2021-05-26	Gilead Sciences, Inc.	Capsid inhibitors for the treatment of hiv
CA3157275A1 (en)	2019-11-26	2021-06-03	Elena BEKERMAN	Capsid inhibitors for the prevention of hiv
CN115996925A (zh)	2020-06-25	2023-04-21	吉利德科学公司	用于治疗hiv的衣壳抑制剂

2017
- 2017-08-17 CN CN202010662665.4A patent/CN111793061A/zh active Pending
- 2017-08-17 CA CA3021227A patent/CA3021227C/en active Active
- 2017-08-17 ES ES17758388T patent/ES2746374T3/es active Active
- 2017-08-17 DK DK17758388.7T patent/DK3347352T3/da active
- 2017-08-17 CN CN201780063636.2A patent/CN109890808B/zh active Active
- 2017-08-17 PL PL19178148.3T patent/PL3597646T3/pl unknown
- 2017-08-17 PT PT17758388T patent/PT3347352T/pt unknown
- 2017-08-17 HU HUE19178148A patent/HUE063811T2/hu unknown
- 2017-08-17 PE PE2020000548A patent/PE20211427A1/es unknown
- 2017-08-17 PE PE2019000375A patent/PE20190910A1/es unknown
- 2017-08-17 UA UAA201901739 patent/UA121630C2/uk unknown
- 2017-08-17 PT PT191781483T patent/PT3597646T/pt unknown
- 2017-08-17 SI SI201730077T patent/SI3347352T1/sl unknown
- 2017-08-17 KR KR1020237000165A patent/KR20230011471A/ko not_active Application Discontinuation
- 2017-08-17 HR HRP20231018TT patent/HRP20231018T1/hr unknown
- 2017-08-17 KR KR1020207032788A patent/KR20200131351A/ko not_active Application Discontinuation
- 2017-08-17 CR CR20190084A patent/CR20190084A/es unknown
- 2017-08-17 EP EP19178148.3A patent/EP3597646B1/en active Active
- 2017-08-17 TW TW109146483A patent/TW202138365A/zh unknown
- 2017-08-17 HU HUE17758388A patent/HUE045137T2/hu unknown
- 2017-08-17 TW TW108108262A patent/TWI715944B/zh active
- 2017-08-17 FI FIEP19178148.3T patent/FI3597646T3/fi active
- 2017-08-17 LT LTEP17758388.7T patent/LT3347352T/lt unknown
- 2017-08-17 TW TW106127987A patent/TWI664966B/zh active
- 2017-08-17 LT LTEP19178148.3T patent/LT3597646T/lt unknown
- 2017-08-17 BR BR122020001791-0A patent/BR122020001791B1/pt active IP Right Grant
- 2017-08-17 SG SG10201912535VA patent/SG10201912535VA/en unknown
- 2017-08-17 AU AU2017312102A patent/AU2017312102B2/en active Active
- 2017-08-17 MA MA42795A patent/MA42795B1/fr unknown
- 2017-08-17 ES ES19178148T patent/ES2954514T3/es active Active
- 2017-08-17 DK DK19178148.3T patent/DK3597646T3/da active
- 2017-08-17 WO PCT/US2017/047416 patent/WO2018035359A1/en active Application Filing
- 2017-08-17 MA MA050673A patent/MA50673A/fr unknown
- 2017-08-17 NZ NZ750706A patent/NZ750706A/en unknown
- 2017-08-17 SG SG11201808944QA patent/SG11201808944QA/en unknown
- 2017-08-17 BR BR112018071678-2A patent/BR112018071678B1/pt active Search and Examination
- 2017-08-17 PL PL17758388T patent/PL3347352T3/pl unknown
- 2017-08-17 MY MYPI2019000877A patent/MY191466A/en unknown
- 2017-08-17 KR KR1020197007456A patent/KR102180740B1/ko active IP Right Grant
- 2017-08-17 SI SI201731404T patent/SI3597646T1/sl unknown
- 2017-08-17 EP EP17758388.7A patent/EP3347352B1/en active Active
- 2017-08-17 JP JP2019508953A patent/JP6716785B2/ja active Active
- 2017-08-17 US US15/680,041 patent/US10071985B2/en active Active
- 2017-08-17 KR KR1020247014103A patent/KR20240070646A/ko active Search and Examination
- 2017-08-17 UY UY0001037367A patent/UY37367A/es not_active Application Discontinuation
- 2017-08-17 MX MX2018012905A patent/MX369307B/es active IP Right Grant
- 2017-08-17 EP EP23179840.6A patent/EP4265299A3/en active Pending
2018
- 2018-06-25 US US16/016,718 patent/US10654827B2/en active Active
- 2018-12-13 HK HK18116015.7A patent/HK1256904B/zh unknown
- 2018-12-16 JO JOP/2018/0123A patent/JOP20180123A1/ar unknown
2019
- 2019-02-04 IL IL264644A patent/IL264644B/en active IP Right Grant
- 2019-02-15 CO CONC2019/0001379A patent/CO2019001379A2/es unknown
- 2019-02-15 CL CL2019000415A patent/CL2019000415A1/es unknown
- 2019-02-15 PH PH12019500335A patent/PH12019500335A1/en unknown
- 2019-02-15 DO DO2019000033A patent/DOP2019000033A/es unknown
- 2019-02-15 EC ECSENADI201911209A patent/ECSP19011209A/es unknown
- 2019-02-18 SA SA519401123A patent/SA519401123B1/ar unknown
- 2019-03-07 ZA ZA2019/01430A patent/ZA201901430B/en unknown
- 2019-09-13 CY CY20191100958T patent/CY1122296T1/el unknown
- 2019-11-25 US US16/694,332 patent/US11993583B2/en active Active
2020
- 2020-03-18 JP JP2020048130A patent/JP2020111592A/ja not_active Withdrawn
- 2020-04-02 AU AU2020202331A patent/AU2020202331C1/en active Active
- 2020-10-19 JP JP2020175151A patent/JP2021008516A/ja active Pending
2021
- 2021-08-26 AU AU2021221855A patent/AU2021221855B2/en active Active
2022
- 2022-10-27 JP JP2022172416A patent/JP2023011754A/ja not_active Withdrawn
- 2022-12-14 HU HUS2200053C patent/HUS2200053I1/hu unknown
- 2022-12-16 NO NO2022059C patent/NO2022059I1/no unknown
- 2022-12-16 FR FR22C1063C patent/FR22C1063I2/fr active Active
- 2022-12-22 CY CY2022039C patent/CY2022039I1/el unknown
2023
- 2023-01-05 LT LTPA2023501C patent/LTPA2023501I1/lt unknown
- 2023-01-11 NL NL301212C patent/NL301212I2/nl unknown
- 2023-11-27 AU AU2023271739A patent/AU2023271739A1/en active Pending

Also Published As

Publication number	Publication date
US10654827B2 (en)	2020-05-19
EP3347352B1 (en)	2019-07-03
HK1256904B (zh)	2020-07-17
MA42795A (fr)	2019-07-03
AU2020202331A1 (en)	2020-04-23
FI3597646T3 (fi)	2023-09-07
NL301212I1 (lt)	2023-01-12
SA519401123B1 (ar)	2022-11-09
US20200262815A1 (en)	2020-08-20
TW201811327A (zh)	2018-04-01
ES2746374T3 (es)	2020-03-05
DOP2019000033A (es)	2019-03-15
EP3597646A1 (en)	2020-01-22
NO2022059I1 (no)	2022-12-16
FR22C1063I1 (fr)	2023-02-03
LTPA2023501I1 (lt)	2023-02-10
IL264644B (en)	2019-09-26
MX369307B (es)	2019-11-05
PE20190910A1 (es)	2019-06-26
MY191466A (en)	2022-06-28
PL3347352T3 (pl)	2019-12-31
AU2020202331B2 (en)	2021-05-27
ECSP19011209A (es)	2019-02-28
BR112018071678B1 (pt)	2021-01-26
CA3021227C (en)	2020-11-03
EP4265299A2 (en)	2023-10-25
LT3597646T (lt)	2023-09-25
NZ750706A (en)	2020-07-31
PT3347352T (pt)	2019-09-24
TWI715944B (zh)	2021-01-11
JP6716785B2 (ja)	2020-07-01
CY1122296T1 (el)	2021-01-27
AU2021221855B2 (en)	2023-08-31
CR20190084A (es)	2019-05-02
KR20200131351A (ko)	2020-11-23
US20180051005A1 (en)	2018-02-22
TW202342449A (zh)	2023-11-01
UY37367A (es)	2018-03-23
ES2954514T3 (es)	2023-11-22
BR122020001791B1 (pt)	2022-01-25
KR102180740B1 (ko)	2020-11-20
FR22C1063I2 (fr)	2023-12-15
JP2023011754A (ja)	2023-01-24
EP3347352A1 (en)	2018-07-18
PE20211427A1 (es)	2021-08-03
CO2019001379A2 (es)	2019-02-19
DK3347352T3 (da)	2019-08-26
KR20240070646A (ko)	2024-05-21
SG10201912535VA (en)	2020-02-27
EP4265299A3 (en)	2024-01-17
MA42795B1 (fr)	2019-08-30
CN111793061A (zh)	2020-10-20
DK3597646T3 (da)	2023-09-04
HUE045137T2 (hu)	2019-12-30
JOP20180123A1 (ar)	2019-01-30
AU2017312102B2 (en)	2020-03-05
CY2022039I2 (el)	2023-01-27
CN109890808B (zh)	2020-08-07
PH12019500335A1 (en)	2019-11-11
SI3347352T1 (sl)	2019-08-30
HRP20231018T1 (hr)	2023-12-08
HUE063811T2 (hu)	2024-02-28
CN109890808A (zh)	2019-06-14
JP2019528280A (ja)	2019-10-10
ZA201901430B (en)	2021-09-29
UA121630C2 (lt)	2020-06-25
WO2018035359A1 (en)	2018-02-22
TW202138365A (zh)	2021-10-16
HUS2200053I1 (hu)	2023-01-28
JP2020111592A (ja)	2020-07-27
CA3021227A1 (en)	2018-02-22
MA50673A (fr)	2020-08-05
NL301212I2 (nl)	2023-04-06
AU2021221855A1 (en)	2021-09-23
JP2021008516A (ja)	2021-01-28
MX2018012905A (es)	2019-01-30
US10071985B2 (en)	2018-09-11
BR112018071678A2 (pt)	2019-02-19
TWI664966B (zh)	2019-07-11
KR20230011471A (ko)	2023-01-20
AU2017312102A1 (en)	2019-03-07
AU2023271739A1 (en)	2023-12-14
SI3597646T1 (sl)	2023-10-30
US11993583B2 (en)	2024-05-28
TW201922711A (zh)	2019-06-16
CL2019000415A1 (es)	2019-06-21
PT3597646T (pt)	2023-09-11
EP3597646B1 (en)	2023-06-21
AU2020202331C1 (en)	2021-08-26
SG11201808944QA (en)	2018-11-29
US20180370950A1 (en)	2018-12-27
CY2022039I1 (el)	2023-01-27
KR20190039431A (ko)	2019-04-11
PL3597646T3 (pl)	2023-12-11

Publication	Publication Date	Title
HUS2200053I1 (hu)	2023-01-28	HIV vírusfertõzés megelõzõ vagy terápiás kezelésére alkalmas terápiás vegyületek
IL263972A (en)	2019-01-31	Dihydropyranopyrimidines for the treatment of viral infections
HK1251554A1 (zh)	2019-02-01	用於治療和預防病毒感染的新的取代的氨基噻唑並嘧啶二酮
HK1248711A1 (zh)	2018-10-19	用於治療和預防病毒感染的新的取代的氨基噻唑並嘧啶二酮
EP3490987A4 (en)	2020-01-15	NOVEL THERAPEUTIC AGENTS FOR THE TREATMENT OF HBV INFECTION.
IL284255A (en)	2021-07-29	7-substituted sulfonimidylpurinone compounds for the treatment and prevention of viral infection
EP3474863A4 (en)	2020-03-25	PHOSPHORAMIDATE FOR TREATING THE HEPATITIS C VIRUS
IL280769A (en)	2021-04-29	New sulfonimidylpurinone compounds and their history for the treatment and prevention of virus infection
PT3519569T (pt)	2021-03-04	Vetores de vírus adenoassociados para o tratamento de mucopolissacaridoses
EP3370723A4 (en)	2019-06-19	TREATMENT OF HEPATITIS DELTA VIRUS INFECTION
EP3137078A4 (en)	2017-11-15	Treatment of hepatitis delta virus infection
EP3226973A4 (en)	2018-05-30	Treatment of hepatitis delta virus infection
EP3448377A4 (en)	2019-12-25	METHODS FOR THE TREATMENT OF AN INFECTION
ZA201900770B (en)	2019-12-18	7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
LT3504210T (lt)	2021-05-10	Nauji 7 padėtyje pakeisti sulfonimidoilpurinono junginiai, skirti viruso sukeliamos infekcijos gydymui ir profilaktikai